Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena

News provided by

Mar 05, 2014, 08:32 ET

NEW YORK, March 5, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Review released its analysts' notes regarding NuVasive, Inc. (NASDAQ: NUVA), IPC The Hospitalist Company, Inc. (NASDAQ: IPCM), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), ICU Medical, Inc. (NASDAQ: ICUI), and Prothena Corporation PLC (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

NuVasive, Inc. Analyst Notes

On March 3, 2014, NuVasive, Inc. (NuVasive) reported Q4 2013 and full year 2013 financial results. During the quarter, the Company's revenue came in at $190.8 million, up 15.1% YoY, while full year total revenue of $685.2 million was up 10.5% YoY. Q4 2013 net income attributable to NuVasive was $6.0 million, or $0.13 per diluted share, compared to a net loss of $2.7 million, or $0.06 loss per diluted share, in Q4 2012. Full-year 2013 net income attributable to the Company was $7.9 million, or $0.17 per diluted share, compared to $3.1 million, or $0.07 per diluted share, in full year 2012. "2013 results clearly demonstrate that NuVasive's market share taking strategy is thriving. Importantly, we are cultivating the drivers that will support top and bottom line growth for many years to come. We are leveraging our unrivaled years of experience and research to continue championing the global market conversion toward less invasive spine solutions. And our commitment to innovation has conceived a pipeline that may dwarf all that we have accomplished so far," said Alex Lukianov, Chairman and CEO of NuVasive. The full analyst notes on NuVasive, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/NUVA/report.pdf

IPC The Hospitalist Company, Inc. Analyst Notes

On March 3, 2014, IPC The Hospitalist Company, Inc. (IPC) announced the appointment of John H. Cassin to the position of Executive Director for the Company's Colorado region. Under the new role, Cassin will be responsible for the operational supervision of IPC's Colorado regional services for both acute and post-acute care business, as well as for delivering on the Company's ongoing commitment to align its clinicians with the operational goals of client facilities and payers. According to IPC, Cassin will report directly to Glenn Appelbaum, the Company's Senior Vice President for Operations. Prior to joining the Company, Cassin served as Regional Vice President of Operations at Sound Physicians. The full analyst notes on IPC The Hospitalist Company, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/IPCM/report.pdf

Portola Pharmaceuticals, Inc. Analyst Notes

On February 27, 2014, Portola Pharmaceuticals, Inc. (Portola) reported Q4 2013 and full-year 2013 financial results. In Q4 2013, the Company's collaboration and license revenue grew 5.1% YoY to $2.1 million, while full year 2013 collaboration and license revenue of $10.5 million was down 85.4% YoY. Q4 2013 net loss stood at $25.1 million, or $0.63 loss per diluted share, compared to a net loss of $13.8 million, or $10.02 loss per diluted share, in Q4 2012. Full year 2013 net loss was $83.4 million, compared to net income of $11.4 million in full year 2012. "We have a clear strategy focused on biomarker or genetic approaches to clinical development that we believe will increase the probability of clinical, regulatory and commercial success of our late-stage pipeline. Additionally, we believe we currently have sufficient capital to independently advance our three late-stage proprietary assets to value-creating clinical and manufacturing milestones through 2015," said William Lis, CEO of Portola. The full analyst notes on Portola Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/PTLA/report.pdf

ICU Medical, Inc. Analyst Notes

On March 3, 2014, ICU Medical, Inc. (ICU) announced that it will be participating at the 26^th Annual ROTH Conference to be held from March 9 to March 12, 2014 at the Ritz-Carlton Hotel in Laguna Niguel, California. According to ICU, its CEO Scott Lamb is scheduled to present on March 10, 2014 at 12:30 p.m. PT. The presentation will be webcast live and can be accessed by going to the Company's website. The full analyst notes on ICU Medical, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03052014/ICUI/report.pdf

Prothena Corporation PLC Analyst Notes

On March 3, 2014, Prothena Corporation PLC (Prothena) announced the promotion of Tara Nickerson, PhD, MBA, to the position of Chief Business Officer. Under the position, Dr. Nickerson will be responsible for leading corporate and business development, as well as alliance management efforts of the Company. Prior to the promotion, Dr. Nickerson served as Prothena's Head of Corporate and Business Development. Commenting on the promotion, Dr. Dale Schenk, President and CEO of Prothena said, "Tara has brought significant business and biotechnology expertise to Prothena since our inception. As our Chief Business Officer, she can provide critical leadership to advance our research and clinical pipeline." The full analyst notes on Prothena Corporation PLC are available to download free of charge at:

http://www.AnalystsReview.com/03052014/PRTA/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review